SMMT Stock Overview
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America.
Notes are coming soon
Summit Therapeutics Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.14|
|52 Week High||US$5.78|
|52 Week Low||US$0.66|
|1 Month Change||-35.79%|
|3 Month Change||204.85%|
|1 Year Change||52.43%|
|3 Year Change||88.02%|
|5 Year Change||-70.38%|
|Change since IPO||-69.48%|
Recent News & Updates
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash WiselyDec 29
Summit Therapeutics slips on plans to terminate study for lead candidateOct 04
Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its PortfolioAug 17
Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23MAug 11
Summit to explore additional trial for its bacteria-induced colon infection drugJul 14
Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn SituationApr 29
Summit Therapeutics - Disappointing Data But Not An Outright FailureDec 23
Summit Therapeutics: A Full Investment Analysis Of This Antibiotic InnovatorJun 22
Summit Therapeutics to join Russell 3000 IndexJun 08
|SMMT||US Biotechs||US Market|
Return vs Industry: SMMT exceeded the US Biotechs industry which returned 4.5% over the past year.
Return vs Market: SMMT exceeded the US Market which returned -8.5% over the past year.
|SMMT Average Weekly Movement||61.8%|
|Biotechs Industry Average Movement||12.1%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||17.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: SMMT is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 62% a week.
Volatility Over Time: SMMT's weekly volatility has increased from 34% to 62% over the past year.
About the Company
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company’s lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI.
Summit Therapeutics Inc. Fundamentals Summary
|SMMT fundamental statistics|
Is SMMT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SMMT income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.39|
|Net Profit Margin||-9,064.02%|
How did SMMT perform over the long term?See historical performance and comparison